Importance Of Adherence To Bcr-abl Tyrosine-kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia.

dc.creatorde Almeida, Maria Helena
dc.creatorFogliatto, Laura
dc.creatorCouto, Dulce
dc.date2014
dc.date2015-11-27T13:42:05Z
dc.date2015-11-27T13:42:05Z
dc.date.accessioned2018-03-29T01:20:02Z
dc.date.available2018-03-29T01:20:02Z
dc.identifierRevista Brasileira De Hematologia E Hemoterapia. v. 36, n. 1, p. 54-9, 2014.
dc.identifier1516-8484
dc.identifier10.5581/1516-8484.20140014
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/24624037
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/201214
dc.identifier24624037
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1301447
dc.descriptionTreatment of chronic myeloid leukemia with BCR-ABL tyrosine kinase inhibitors requires full adherence in order to maximize the likelihood of achieving optimal responses, and to minimize healthcare costs. In this article, we review some of the methods available for assessing compliance, the main consequences of nonadherence on treatment outcomes, major factors commonly associated with poor compliance, a few successful measures for improving adherence and the most accepted recommendations for proactively managing adverse events.
dc.description36
dc.description54-9
dc.languageeng
dc.relationRevista Brasileira De Hematologia E Hemoterapia
dc.relationRev Bras Hematol Hemoter
dc.rightsaberto
dc.rights
dc.sourcePubMed
dc.subjectBcr-abl Positive
dc.subjectLeukemia, Chronic Myeloid
dc.subjectPatient Compliance
dc.subjectTherapeutics
dc.titleImportance Of Adherence To Bcr-abl Tyrosine-kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución